1.	Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
2.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
3.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
4.	Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML Phase: Phase III Type: Treatment Status: Active Age: 50 to 75 Sponsor: Other Protocol IDs: BMT190, 97843, 5567, NCT00568633
5.	Randomized Allogeneic Azacitidine Study Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2008-0503, NCT00887068
6.	TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TK008, 2009-012973-37, NCT00914628
7.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
8.	Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 709, U01HL069294, U01HL069294-05, 0901, NCT01339910
9.	Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101) Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 715, 2U10HL069294-11, NCT01597778
10.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
11.	Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CB001, UMN-2003LS055, UMN-MT2003-20, VIACELL-CB001-03, UMN-0310M3141, NCT00089596
12.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
13.	Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2005-0508, NCT00402558
14.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
15.	Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
16.	Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL Phase: Phase II, Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: L 9471, NCT00529360
17.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
18.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
19.	A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 070768, NCT00808080
20.	Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 montha to 70 Sponsor: Other Protocol IDs: J1055, NA_00039823, NCT01203722
21.	Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CLT008-02, NCT01297543
22.	Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 6 months to 85 Sponsor: Other Protocol IDs: J1151, NA_00048378, NCT01342289
23.	Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201112026, NCT01413568
24.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
25.	CNDO-109-AANK for AML in First Complete Remission (CR1) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CNDO109-001, NCT01520558